Your Children's Eyes Are In Great Hands With The Latest Word On MiYOSMART LENSES

Does your child struggle with distance vision, finding it difficult to see across the classroom or outside? It’s likely your little one is contending with the problems brought about by myopia.

According to recent findings, the World Health Organization expects the number of people with myopic vision issues to increase to nearly 2.5 billion by 2050*. This increase has optometrists searching for refined and improved ways to control myopia progression in their patients, especially children.

HERE’S THE GOOD NEWS!

Myopia treatment methods have become the centre of attention recently. Specifically, such avenues as:

  1. 1. The use of atropine in eye-drop form.
  2. 2. State-of-the-art prescription lens technology
  3. 3. Tailor-purposed contact lenses.

In recent events, five well-known experts in their fields (such as pediatric optometrists) on myopia from Europe and Asia held an advisory meeting. Also discussed was a combination treatment approach with atropine and optical appliances (prescription eyewear) for myopia management.

The experts reached a consensus! By combining the regular wear of MiYOSMART spectacle lenses and the use of atropine drops, experts (working jointly from Europe and Asia) have conferred successful and reliable findings. Furthermore, they note a better control effect with the combination treatment for myopia management in children.

Note what Dr Hakan Kaymak added with his comments on the recent advisory meeting: “The promising early treatment intervention I have seen in my work combining the MiYOSMART spectacle lens and atropine drops is a very exciting development as we continue to seek an evidence-based approach to myopia management in children.”**

In connection to this, no significant changes in binocular vision or visual acuity were reported between using “MiYOSMART spectacle lenses alone or in combination with low dosage atropine.”**

PSST… What is Atropine or Atropine Drops?

Atropine is a medication that has been used for many years to treat conditions like glaucoma and amblyopia (lazy eye). More recently, it is proving to be an effective tool in treating myopia progression in children. Atropine paralyses the ciliary muscles, which are responsible for changing the eyeball’s shape to focus light on the retina. By paralysing these muscles, atropine prevents the eyeball from becoming too elongated. By preventing eyeball shape changes, the progression of myopia is reduced.

Read the full press release here:

CAN YOUR CHILD ACCESS THIS TECHNOLOGY?

Absolutely! At Optical Superstore, we offer the professional services of licensed, independently run optometrists. Moreover, our staff have attained the specific qualifications to dispense the MiYOSMART lens design. Regarding this state-of-the-art technology, we know you need assurance that optical staff have the know-how to ensure your child’s vision is best supported.

There have been impressive strides with the new MiYOSMART lens technology. The reported results show that the future looks bright for young children. So there’s no better time than today to reach out, get in touch, and book a consultation or eye test for the youngest members of your family.

INTERESTED TO READ MORE ABOUT THE PREVIOUS FINDINGS FOR THE MIYOSMART LENS TECHNOLOGY?

CLICK TO READ THE INITIAL MEDIA UPDATE FROM OPTICAL SUPERSTORE.

IN CONCLUSION! The combination treatment of MiYOSMART spectacle lenses and atropine drops produces reliable opportunities for your child! This finding is significant because it provides pediatric optometrists and qualified general consultation optometrists alike with a new tool for slowing myopia progression in their patients.

If you are a parent whose child is affected by myopia, talk to your Optical Superstore optometrist about whether this new treatment option may be right for them.

WE HAVE OVER 60+ PRIME RETAIL OUTLETS/OPTOMETRIST AUSTRALIA LOCATIONS.

Prepare ahead of time and book an appointment online!
Head to our homepage today and click on

BOOK AN EYE TEST